| dc.contributor.author | Cantón-Bulnes, María Luisa | |
| dc.contributor.author | García Garmendia, José Luis | |
| dc.contributor.author | Estella García, Ángel | |
| dc.contributor.author | Fernández-Galilea, Adela | |
| dc.contributor.author | Blanco, Isidro | |
| dc.contributor.author | Estecha-Foncea, María Antonia | |
| dc.contributor.author | Gordillo-Resina, Marina | |
| dc.contributor.author | Rodríguez-Gómez, Jorge | |
| dc.contributor.author | Pineda-Capitán, Jesús | |
| dc.contributor.author | Martínez-Fernández, Carmen | |
| dc.contributor.author | Escoresca-Ortega, Ana | |
| dc.contributor.author | Amaya Villar, Rosario | |
| dc.contributor.author | Mora-Ordóñez, Juan | |
| dc.contributor.author | González-Soto, Sara | |
| dc.contributor.author | Garnacho-Montero, José | |
| dc.contributor.other | Cirugía | es_ES |
| dc.contributor.other | Medicina | es_ES |
| dc.date.accessioned | 2026-10-30T08:46:18Z | |
| dc.date.available | 2026-10-30T08:46:18Z | |
| dc.date.issued | 2026 | |
| dc.identifier.issn | 1435-4373 | |
| dc.identifier.issn | 0934-9723 | |
| dc.identifier.uri | http://hdl.handle.net/10498/40512 | |
| dc.description.abstract | Objectives: The aim of this study was to validate the SeptiCyte® RAPID assay, a molecular test to distinguish sepsis from sterile inflammation, by determining its diagnostic accuracy in critically ill patients who meet criteria for sepsis according to Sepsis-3 definition on ICU admission Design: This is an observational, prospective, and multicenter study.Setting: Carried out in seven hospitals in Andalusia (Spain). A 2.5 mL whole blood sample was collected and tested in a SeptiCyte RAPID kit on a real time PCR platform (IdyllaTM). A score from 0 to 15 (SeptiScore™) was generated that falls into four bands based on the increasing likelihood of infection-positive systemic inflammation. Patients: Patients aged 18 years or older, admitted to the ICU with a diagnosis of sepsis.Main results: We enrolled 354 patients, of whom 86 (24.3%) did not present sepsis at the researchers´ discretion. SeptiCyte® RAPID showed an AUC of [0.84 (CI95% 0.79-0.87)] for differentiating sepsis from sterile systemic inflammation. SeptiCyte® RAPID was significantly better for sepsis diagnosis than CRP [0.75 (CI95% 0.70-0.80)] (p =0.003) but without significant differences with PCT [0.80 (CI95% 0.75-0.84)]. SeptiScore distribution in patients with sepsis was higher than patients with sterile inflammation, with a PPV of 68.8% and 92.2% (Bands 3 and 4) for sepsis diagnosis and a PPV of 100% for sterile inflammation (Band 1). Independent risk factors for sepsis were estimated probability of sepsis [OR 8.02 (CI 95% 4.50-14.28), p<0.001], SeptiScore [OR 1.64 (CI 95% 1.35-1.99), p<0.001], and log procalcitonin [OR 1.68 (CI 95% 1.09-2.59), p=0.020].Conclusions: SeptiCyte® RAPID discriminates sepsis from sterile inflammation in critically ill adults, adding value to the diagnosis of sepsis. Purpose: The aim of this study was to validate the SeptiCyte® RAPID assay, a molecular test to distinguish sepsis from sterile inflammation, by determining its diagnostic accuracy in critically ill patients who meet criteria for sepsis according to Sepsis-3 definition on ICU admission.Methods: This is an observational, prospective, and multicenter study. Carried out in seven hospitals in Andalusia (Spain). A 2.5 mL whole blood sample was collected and tested in a SeptiCyte RAPID kit on a real time PCR platform (IdyllaTM). A score from 0 to 15 (SeptiScore™) was generated that falls into four bands based on the increasing likelihood of infection-positive systemic inflammation.Patients aged 18 years or older, admitted to the ICU with a diagnosis of sepsis were included. Results: We enrolled 353 patients, of whom 86 (23.7%) did not present sepsis at the researchers´ discretion. SeptiCyte® RAPID showed an AUC of [0.84 (CI95% 0.79-0.87)] for differentiating sepsis from sterile systemic inflammation. SeptiCyte® RAPID was significantly better for sepsis diagnosis than CRP [0.75 (CI95% 0.70-0.80)] (p =0.003) but without significant differences with PCT [0.80 (CI95% 0.75-0.84)]. SeptiScore distribution in patients with sepsis was higher than patients with sterile inflammation, with a PPV of 68.8% and 92.2% (Bands 3 and 4) for sepsis diagnosis and a PPV of 100% for sterile inflammation (Band 1). Independent risk factors for sepsis were physicians´ subjective likelihood of sepsis [intermediate probabilty OR 4.55 (95% CI 1.61-12.83), p=0.004 and high probabilty OR 72.04 (95% CI 20.85-248.93), p<0.001], SeptiScore [OR 1.65 (95% CI 1.32-2.07), p<0.001], and log procalcitonin [OR 1.74 (95% CI 1.08-2.79), p=0.022].Conclusions: SeptiCyte® RAPID discriminates sepsis from sterile inflammation in critically ill adults, adding value to the diagnosis of sepsis. | es_ES |
| dc.format | application/pdf | es_ES |
| dc.language.iso | eng | es_ES |
| dc.publisher | Springer Science and Business Media Deutschland GmbH | es_ES |
| dc.rights | Atribución 4.0 Internacional | * |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
| dc.source | European Journal of Clinical Microbiology and Infectious Diseases - 2026, Vol. 45 n.6 pp. 1605-1615 | es_ES |
| dc.subject | Biomarkers | es_ES |
| dc.subject | Diagnosis accuracy | es_ES |
| dc.subject | ICU | es_ES |
| dc.subject | Mortality | es_ES |
| dc.subject | Sepsis | es_ES |
| dc.subject | Septycite | es_ES |
| dc.title | Diagnostic accuracy of SeptiCyte® RAPID to discriminate sepsis from non-infectious critical illness in patients meeting sepsis criteria according to sepsis-3 definition at ICU admission | es_ES |
| dc.type | journal article | es_ES |
| dc.rights.accessRights | open access | es_ES |
| dc.identifier.doi | 10.1007/S10096-026-05431-6 | |
| dc.type.hasVersion | VoR | es_ES |